ROBERT HAROLD ECKEL
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism AURORA, CO NPI 1831289503
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism CO Madrigal Pharmaceuticals All categories
General Payments — all program years on this page
$70,820.40
- Category: General Payments
- Program years: PY2018–2024
- Record count: 92
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $4,173.04 across 8 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $2,375.00 | 2 |
| Honoraria | $1,470.00 | 1 |
| Food and Beverage | $328.04 | 5 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Madrigal Pharmaceuticals | $1,470.00 | 1 |
| Lilly USA, LLC | $1,250.00 | 1 |
| Novo Nordisk AS | $1,181.15 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $182.43 | 2 |
| Astellas Pharma US Inc | $59.07 | 1 |
| Acerta Pharma LLC | $30.39 | 1 |
By program year
Records — PY2024 (8)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1086844789 | Novartis Pharmaceuticals Corporation | $68.35 | 01/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1086844805 | Novartis Pharmaceuticals Corporation | $114.08 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1097497938 | Novo Nordisk Inc | $56.15 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1097725355 | Novo Nordisk Inc | $1,125.00 | 11/22/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1105662998 | AstraZeneca Pharmaceuticals LP | $30.39 | 06/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1135391513 | Lilly USA, LLC | $1,250.00 | 04/10/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1139378582 | Astellas Pharma US Inc | $59.07 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1144164997 | Madrigal Pharmaceuticals | $1,470.00 | 12/05/2024 | Honoraria | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.